Janssen’s Spravato Enters US Market With Enhanced REMS And Plans For A Monotherapy Trial
Executive Summary
Restrictive risk management plan for antidepressant nasal spray requires patients be monitored for two hours after dosing and enroll in a patient registry; Janssen has agreed to conduct a monotherapy efficacy trial as a postmarketing commitment.
You may also be interested in...
J&J Hedges On 2025 Pharma Revenue Outlook
The company admitted it may not meet a goal set in 2021 to reach a $60bn pharmaceutical revenue target in 2025.
Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake
The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.
Psychiatric Disorders Markets: Depression, Bipolar Disorder And Schizophrenia
PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.